beyond
colgat organ top-line growth improv in-lin nearli global
hpc yet share key oral market still flat see need
higher invest beyond year shape alongsid improv
macro somewhat eas comp look ahead maintain
expect lower oper marginw forecast lsd ep growth next
year vs consensu hsd year earn risk near-peak valuat
determin under-perform rate
momentum visibl organ sale expect deliv
high-end organ growth guidanc year
driven primarili better result emerg market price/mix gain
also rais organ top-line growth forecast next year
invest come advertis ytd expect
increas similar level given continu share loss
volum declin germani franc drove slowdown
organ sale across develop market believ addit invest
behind brand innov may requir
estim valuat maintain ep estim
y/i guidanc msd declin rais ep
reflect filorga acquisit target increas
base ep discount risk
recaptur market share reinvest lead better growth margin
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
colgate-palmol lead global consum product compani
tightli focus oral person pet
nutrit colgat sell product countri
territori around world
price jul rate under-perform target price analyst kaumil gajrawala
profit tax
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
share could trade high end cl averag
acceler high-end msd growth expect stabil
gross margin revers profit loss larger market
total ebit margin could expand next coupl
year would impli ep
share could trade low end cl averag
deceler region player captur share could
lead organ sale growth lsd expect margin
de-lever need reinvest heavili market
increas commod pressur keep ebit margin
sale would impli ep
 close
compani mention price
